GeneDx provides clinical genomic testing focused on rare disease diagnosis, particularly exome and genome sequencing for pediatric and complex cases. Laboratories analyze DNA to identify disease-causing variants and support clinicians when standard tests fail to explain symptoms. The company serves hospitals, genetics clinics, and specialists who need high-depth sequencing and interpretation for undiagnosed patients.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 102.7 | — | 10.8 | — |
| Q3 2025 | 116.7 | — | -7.6 | — |
| Q4 2025 | 121 | — | -17.7 | — |
| Q1 2026 | 102.3 | — | -63.3 | — |
| Q2 2026 | 114.4 | 11.4% | -17.7 | -264.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: National Energy Services Reunited Corp. (NESR), BioLife Solutions, Inc. (BLFS), ADARx Pharmaceuticals, Inc. (ADRX), Xeris Biopharma Holdings, Inc. (XERS), German American Bancorp, Inc. (GABC), Agios Pharmaceuticals, Inc. (AGIO)